Medscape is available in 5 Language Editions – Choose your Edition here.


Pancoast Syndrome

  • Author: Karl J D'Silva, MD; Chief Editor: Jules E Harris, MD, FACP, FRCPC  more...
Updated: Mar 28, 2014


Pancoast syndrome (Pancoast’s syndrome) is characterized by a malignant neoplasm of the superior sulcus of the lung (lung cancer) with destructive lesions of the thoracic inlet and involvement of the brachial plexus and cervical sympathetic nerves (stellate ganglion).[1, 2, 3] This is accompanied by the following:

  • Severe pain in the shoulder region radiating toward the axilla and scapula along the ulnar aspect of the muscles of the hand
  • Atrophy of hand and arm muscles
  • Horner syndrome ( ptosis, miosis, hemianhidrosis, enophthalmos)
  • Compression of the blood vessels with edema

Most Pancoast tumors are squamous cell carcinomas (SCCs) or adenocarcinomas; only 3-5% are small cell carcinomas. Squamous cell carcinoma occurs more frequently, although large cell and undifferentiated types are also common. Adenocarcinoma is sometimes found in this location and can even be metastatic. Involvement of the phrenic or recurrent laryngeal nerve or superior vena cava obstruction is not representative of the classic Pancoast tumor.

Careful assessment and appropriate staging are performed before surgery, and selected patients are administered preoperative irradiation of 30 Gy over 2 weeks. After an interval of 2-4 weeks, surgical resection of the chest wall and lower brachial plexus and en bloc lung resection produces a 5-year survival rate of 30%. Contraindications to surgical management include the following:

  • Extension of the tumor into the neck or vertebrae
  • Presence of substantial mediastinal lymph nodes
  • Peripheral tumor dissemination

Protocols that use combinations of irradiation, chemotherapy, and surgery are currently being studied to determine the best therapy.



Pancoast tumors are a subset of lung cancers that invade the apical chest wall. Because of their location in the pleural apex, they invade adjoining tissue. Although other tumors may have a similar clinical presentation because of their location at the thoracic inlet, the most common cause is believed to be a bronchogenic carcinoma arising in or near the superior sulcus and invading adjacent extrathoracic structures by direct extension. Location, rather than pathology or histology of origin, is significant in producing the tumor’s characteristic clinical pattern.[4]

The bulk of a true Pancoast tumor is extrathoracic, originating in an extreme peripheral location with a plaquelike extension over the lung apex and principally involving the chest wall structures rather than the underlying lung parenchyma. Bronchogenic carcinomas occurring in the narrow confines of the thoracic inlet invade the lymphatic vessels in the endothoracic fascia and include, by direct extension, the intercostal nerves, the lower roots of the brachial plexus, the stellate ganglion, the sympathetic chain, and adjacent ribs and vertebrae.

Carcinomas in the superior pulmonary sulcus produce Pancoast syndrome, thus causing pain in the shoulder and along the ulnar nerve distribution of the arm and hand.[5] (These carcinomas also cause Horner syndrome.) These apical lung tumors tend to be locally invasive early. In the absence of metastases and regional nodal involvement, these apical cancers can be successfully treated.

The tumor may invade the bony structures of the chest. The first or second thoracic vertebra or the first, second, or third ribs may be invaded. In a review of 60 patients with Pancoast tumors, Maggi et al found radiographic evidence of rib erosion in 50%; an almost equal percentage demonstrated involvement of the first or second rib, and 20% had involvement of the third rib. One patient had involvement of all 3 ribs.[6]

The tumor can also invade the first or second thoracic vertebral bodies or intervertebral foramina. From this point, it can extend to the spinal cord and result in cord compression. The subclavian vein or artery may also be invaded.



The overwhelming majority of cases of Pancoast syndrome are non–small cell lung carcinoma (NSCLC), with more than 95% located in the superior sulcus. The most common varieties are SCC and adenocarcinoma; large cell carcinoma has also been reported.

Although quite rare (responsible for fewer than 5% percent of cases in most series), small cell carcinoma is also observed. Maggi et al reported only 3 patients with small cell carcinoma in their 1994 series of 60 patients.[6] More typically, small cell carcinoma manifests in a central rather than a peripheral location.

Although NSCLC is by far the most common cause of Pancoast syndrome, the list of differential diagnoses is broad. Because of the wide variety of diseases that can produce Pancoast syndrome, a histologic diagnosis is mandatory before definitive treatment is initiated.

In rare instances, benign tumors such as desmoid tumors (case records of the Massachusetts General Hospital: weekly clinicopathological exercises, 2000) or hemangiopericytoma[7] may cause the condition. Adenoid cystic carcinoma,[8] metastatic carcinoma,[9] lymphoma,[10] and thyroid carcinoma[11] have all been associated with the syndrome. Infectious processes, including bacterial[12, 13] and fungal infections[14, 15] may also be involved.

Other causes include lymphomatoid granulomatosis, vascular aneurysms, amyloid nodules, and cervical rib syndrome. Inflammatory pseudotumor (plasma cell granuloma), mycotic subclavian artery aneurysm, and carotid pseudoaneurysm in a child (caused by a hydatid cyst) have been reported.

Risk factors are similar for almost all lung cancers. They include prior prolonged asbestos exposure, exposure to industrial elements (eg, gold, nickel), smoking, and secondary smoke exposure.



Overall, Pancoast tumors are much less common than other lung cancers, accounting for fewer than 5% of these cancers (1-3% in various previous series).[16, 17] Originally deemed universally fatal, Pancoast tumors are now amenable to curative treatment because of improvements in combined modality therapy and development of new techniques for resection.



The prognosis for Pancoast syndrome is stage-dependent. Adverse prognostic factors have been identified and include the following:

  • Presence of Horner syndrome
  • Involvement of mediastinal lymph nodes
  • Incomplete resection
  • Involvement of supraclavicular lymph node
  • Vertebral body invasion

To date, no patient with the first 3 prognostic factors has survived for 5 years.

Distant disease limits survival. The brain is the frequent site of failure for superior sulcus tumors. The authors recommend careful surveillance for brain metastasis during and after the therapy. The authors also recommend obtaining brain imaging prior to surgery in patients receiving induction therapy for the primary tumor.

Mortality and survival

Attar et al reported a median survival of 36.8 months in patients with T3 lesions undergoing combined modality treatment; median survival was only 6.4 months if the patient had T4 disease.[18]

Overall survival data were summarized by Detterbeck, who noted that 5-year survival rates ranged from 15% to 56%.[19] Of the 104 patients treated by Attar and coworkers, 7 (~7%) were 5-year survivors and 3 (~3%) were 10-year survivors.[18] Another study demonstrated surgical morbidity rates of 7-38%, with mortality ranging from 5% to 10%.[20]

For neoplastic causes, predictors of 5-year survival are weight loss, supraclavicular fossa or vertebral body involvement, disease stage, and surgical treatment. A study by an MD Anderson group reported the following findings[21] :

  • For patients with stage IIB disease, the 5-year survival rate was 47%, whereas for those with stage IIIA and IIIB disease, it was 14% and 16%, respectively
  • In patients with stage IIB disease, surgical treatment and weight loss were significant independent predictors of 5-year survival
  • Among patients with stage IIIA disease, the only predictor of survival was the Karnofsky performance score
  • In patients with stage IIIB disease, the only independent predictor of survival was a right superior sulcus location, which was associated with a worse 5-year survival rate than a left superior sulcus location
  • Compared with patients who had squamous cell tumors, more patients with adenocarcinoma had cerebral metastases within 5 years


Locoregional relapse is common despite preoperative or postoperative radiation therapy. Muscolino et al found locoregional recurrence in 60% of patients treated with a combined radiosurgical approach. Ginsberg et al found that 94 of their 124 patients had recurrence of disease, with 72% of these cases being locoregional at initial recurrence. In two thirds of patients who underwent complete resection, local recurrences were the first site of relapse.[16]

This distribution of relapses was noted in several studies reviewed by Detterbeck. In many of these studies, patients received preoperative radiation therapy.[19] In the Memorial Sloan-Kettering experience, additional postoperative brachytherapy was administered to achieve maximal possible local control; despite these measures, local relapses, and, ultimately, distant relapses, were frequent.[16]

Contributor Information and Disclosures

Karl J D'Silva, MD Assistant Clinical Professor of Medicine, Department of Hematology/Oncology, Lahey Clinic, Sophia Gordon Cancer Center

Karl J D'Silva, MD is a member of the following medical societies: Massachusetts Medical Society

Disclosure: Nothing to disclose.


Sarah K May, MD Consulting Staff, Department of Hematology-Oncology, Caritas Carney Hospital, Commonwealth Hematology-Oncology PC

Disclosure: Nothing to disclose.

Chief Editor

Jules E Harris, MD, FACP, FRCPC Clinical Professor of Medicine, Section of Hematology/Oncology, University of Arizona College of Medicine, Arizona Cancer Center

Jules E Harris, MD, FACP, FRCPC is a member of the following medical societies: American Association for the Advancement of Science, American Society of Hematology, Central Society for Clinical and Translational Research, American Society of Clinical Oncology

Disclosure: Nothing to disclose.


Shabir Bhimji, MD, PhD Locum Cardiothoracic and Vascular Surgeon, Saudi Arabia and Middle East Hospitals

Shabir Bhimji, MD, PhD is a member of the following medical societies: American Cancer Society, American College of Chest Physicians, American Lung Association, and Texas Medical Association

Disclosure: Nothing to disclose.

Shreekanth V Karwande, MBBS Chair, Professor, Department of Surgery, Division of Cardiothoracic Surgery, University of Utah School of Medicine and Medical Center

Shreekanth V Karwande, MBBS is a member of the following medical societies: American Association for Thoracic Surgery, American College of Chest Physicians, American College of Surgeons, American Heart Association, Society of Critical Care Medicine, Society of Thoracic Surgeons, and Western Thoracic Surgical Association

Disclosure: Nothing to disclose.

Jeffrey C Milliken, MD Chief, Division of Cardiothoracic Surgery, University of California at Irvine Medical Center; Clinical Professor, Department of Surgery, University of California, Irvine, School of Medicine

Jeffrey C Milliken, MD is a member of the following medical societies: Alpha Omega Alpha, American Association for Thoracic Surgery, American College of Cardiology, American College of Chest Physicians, American College of Surgeons, American Heart Association, American Society for Artificial Internal Organs, California Medical Association, International Society for Heart and Lung Transplantation, Phi Beta Kappa, Society of Thoracic Surgeons, Southwest Oncology Group, and Western Surgical Association

Disclosure: Nothing to disclose.

Michael Perry, MD, MS, MACP Nellie B Smith Chair of Oncology Emeritus, Director, Division of Hematology and Medical Oncology, Deputy Director, Ellis Fischel Cancer Center, University of Missouri-Columbia School of Medicine

Michael Perry, MD, MS, MACP is a member of the following medical societies: Alpha Omega Alpha, American Association for Cancer Research, American College of Physicians, American College of Physicians-American Society of Internal Medicine, American Medical Association, American Society of Clinical Oncology, American Society of Hematology, International Association for the Study of Lung Cancer, and Missouri State Medical Association

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

  1. Pancoast HK. Importance of careful roentgen ray investigations of apical chest tumors. JAMA. 1924. 83:1407-1411.

  2. Pancoast HK. Superior pulmonary sulcus tumor: Tumor characterized by pain, Horner's syndrome, destruction of bone and atrophy of hand muscles. JAMA. 1932. 99:1391-1396.

  3. Hare ES. Tumor involving certain nerves. Lond Med Gaz. 1838. 1:16-18.

  4. Paulson DL. Carcinomas in the superior pulmonary sulcus. J Thorac Cardiovasc Surg. 1975 Dec. 70(6):1095-104. [Medline].

  5. Pitz CC, de la Rivière AB, van Swieten HA, Duurkens VA, Lammers JW, van den Bosch JM. Surgical treatment of Pancoast tumours. Eur J Cardiothorac Surg. 2004 Jul. 26(1):202-8. [Medline].

  6. Maggi G, Casadio C, Pischedda F, et al. Combined radiosurgical treatment of Pancoast tumor. Ann Thorac Surg. 1994 Jan. 57(1):198-202. [Medline].

  7. Chong KM, Hennox SC, Sheppard MN. Primary hemangiopericytoma presenting as a Pancoast tumor. Ann Thorac Surg. 1993 Feb. 55(2):9. [Medline].

  8. Hatton MQ, Allen MB, Cooke NJ. Pancoast syndrome: an unusual presentation of adenoid cystic carcinoma. Eur Respir J. 1993 Feb. 6(2):271-2. [Medline].

  9. Amin R. Bilateral Pancoast's syndrome in a patient with carcinoma of the cervix. Gynecol Oncol. 1986 May. 24(1):126-8. [Medline].

  10. Mills PR, Han LY, Dick R, Clarke SW. Pancoast syndrome caused by a high grade B cell lymphoma. Thorax. 1994 Jan. 49(1):92-3. [Medline].

  11. Rabano A, La Sala M, Hernandez P, et al. Thyroid carcinoma presenting as Pancoast's syndrome. Thorax. 1991 Apr. 46(4):270-1. [Medline].

  12. Vandenplas O, Mercenier C, Trigaux JP, et al. Pancoast's syndrome due to Pseudomonas aeruginosa infection of the lung apex. Thorax. 1991 Sep. 46(9):683-4. [Medline].

  13. Gallagher KJ, Jeffrey RR, Kerr KM, Steven MM. Pancoast syndrome: an unusual complication of pulmonary infection by Staphylococcus aureus. Ann Thorac Surg. 1992 May. 53(5):903-4. [Medline].

  14. Simpson FG, Morgan M, Cooke NJ. Pancoast's syndrome associated with invasive aspergillosis. Thorax. 1986 Feb. 41(2):156-7. [Medline].

  15. Mitchell DH, Sorrell TC. Pancoast's syndrome due to pulmonary infection with Cryptococcus neoformans variety gattii. Clin Infect Dis. 1992 May. 14(5):1142-4. [Medline].

  16. Ginsberg RJ, Martini N, Zaman M, et al. Influence of surgical resection and brachytherapy in the management of superior sulcus tumor. Ann Thorac Surg. 1994 Jun. 57(6):1440-5. [Medline].

  17. Johnson DE, Goldberg M. Management of carcinoma of the superior pulmonary sulcus. Oncology (Huntingt). 1997 Jun. 11(6):781-5; discussion 785-6. [Medline].

  18. Attar S, Krasna MJ, Sonett JR, et al. Superior sulcus (Pancoast) tumor: experience with 105 patients. Ann Thorac Surg. 1998 Jul. 66(1):193-8. [Medline].

  19. Detterbeck FC. Pancoast (superior sulcus) tumors. Ann Thorac Surg. 1997 Jun. 63(6):1810-8. [Medline].

  20. Arcasoy SM, Jett JR. Superior pulmonary sulcus tumors and Pancoast's syndrome. N Engl J Med. 1997 Nov 6. 337(19):1370-6. [Medline].

  21. Komaki R, Roth JA, Walsh GL, et al. Outcome predictors for 143 patients with superior sulcus tumors treated by multidisciplinary approach at the University of Texas M. D. Anderson Cancer Center. Int J Radiat Oncol Biol Phys. 2000 Sep 1. 48(2):347-54. [Medline].

  22. Muscolino G, Valente M, Andreani S. Pancoast tumours: clinical assessment and long-term results of combined radiosurgical treatment. Thorax. 1997 Mar. 52(3):284-6. [Medline].

  23. Balcer LJ, Galetta SL. Images in clinical medicine. Pancoast's syndrome. N Engl J Med. 1997 Nov 6. 337(19):1359. [Medline].

  24. Shah H, Anker CJ, Bogart J, Graziano S, Shah CM. Brain: the common site of relapse in patients with pancoast or superior sulcus tumors. J Thorac Oncol. 2006 Nov. 1(9):1020-2. [Medline].

  25. Beale R, Slater R, Hennington M, Keagy B. Pancoast tumor: use of MRI for tumor staging. South Med J. 1992 Dec. 85(12):1260-3. [Medline].

  26. Patz EF Jr. Imaging lung cancer. Semin Oncol. 1999 Oct. 26(5 Suppl 15):21-6. [Medline].

  27. Heelan RT, Demas BE, Caravelli JF, et al. Superior sulcus tumors: CT and MR imaging. Radiology. 1989 Mar. 170(3 Pt 1):637-41. [Medline].

  28. Anderson TM, Moy PM, Holmes EC. Factors affecting survival in superior sulcus tumors. J Clin Oncol. 1986 Nov. 4(11):1598-603. [Medline].

  29. Maxfield RA, Aranda CP. The role of fiberoptic bronchoscopy and transbronchial biopsy in the diagnosis of Pancoast''s tumor. N Y State J Med. 1987 Jun. 87(6):326-9. [Medline].

  30. Paulson DL, Weed TE, Rian RL. Cervical approach for percutaneous needle biopsy of Pancoast tumors. Ann Thorac Surg. 1985 Jun. 39(6):586-7. [Medline].

  31. Shaham D. Semi-invasive and invasive procedures for the diagnosis and staging of lung cancer. I. Percutaneous transthoracic needle biopsy. Radiol Clin North Am. 2000 May. 38(3):525-34. [Medline].

  32. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest. 1997 Jun. 111(6):1710-7. [Medline].

  33. Rusch VW. Management of Pancoast tumours. Lancet Oncol. 2006 Dec. 7(12):997-1005. [Medline].

  34. Dartevelle PG, Chapelier AR, Macchiarini P, et al. Anterior transcervical-thoracic approach for radical resection of lung tumors invading the thoracic inlet. J Thorac Cardiovasc Surg. 1993 Jun. 105(6):1025-34. [Medline].

  35. Uchino K, Tauchi S, Tanaka Y, Nakai R, Tane S, Yoshimura M. [Treatment of superior sulcus tumor]. Kyobu Geka. 2010 Jan. 63(1):18-22. [Medline].

  36. Detterbeck FC, Jones DR, Kernstine KH, Naunheim KS. Lung cancer. Special treatment issues. Chest. 2003 Jan. 123(1 Suppl):244S-258S. [Medline]. [Full Text].

  37. Hilaris BS, Martini N, Wong GY, Nori D. Treatment of superior sulcus tumor (Pancoast tumor). Surg Clin North Am. 1987 Oct. 67(5):965-77. [Medline].

  38. Stanford W, Barnes RP, Tucker AR. Influence of staging in superior sulcus (Pancoast) tumors of the lung. Ann Thorac Surg. 1980 May. 29(5):406-9. [Medline].

  39. Shaw RR, Paulson DL, Kee JL. Treatment of Superior Sulcus Tumor by Irradiation Followed by Resection. Ann Surg. 1961 Jul. 154(1):29-40. [Medline].

  40. Torre W, Garcia-Franco C, Tamura A, Gurpide A, Lopez-Picazo J, Aristu J, et al. Role of surgery in a multidisciplinary approach to superior sulcus tumors (SST): morbidity and prognostic factors for long-term success after resection. Thorac Cardiovasc Surg. 2009 Sep. 57(6):353-7. [Medline].

  41. Rosell R, Gomez-Codina J, Camps C, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med. 1994 Jan 20. 330(3):153-8. [Medline].

  42. Roth JA, Fossella F, Komaki R, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst. 1994 May 4. 86(9):673-80. [Medline].

  43. Albain KS, Crowley JJ, Turrisi AT, et al. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. J Clin Oncol. 2002 Aug 15. 20(16):3454-60. [Medline].

  44. Langer CJ. Induction or neoadjuvant therapy in resectable non-small cell lung cancer. Semin Oncol. 1999 Oct. 26(5 Suppl 15):34-9. [Medline].

  45. Peedell C, Dunning J, Bapusamy A. Is there a standard of care for the radical management of non-small cell lung cancer involving the apical chest wall (Pancoast tumours)?. Clin Oncol (R Coll Radiol). 2010 Jun. 22(5):334-46. [Medline].

  46. Tamura M, Hoda MA, Klepetko W. Current treatment paradigms of superior sulcus tumours. Eur J Cardiothorac Surg. 2009 Oct. 36(4):747-53. [Medline].

  47. Hubbard MO, Schroeder C, Linden PA. Routine use of staging thoracoscopy for pancoast tumors without overt radiographic chest wall invasion. Surg Laparosc Endosc Percutan Tech. 2011 Apr. 21(2):111-5. [Medline].

  48. Caronia FP, Ruffini E, Lo Monte AI. The use of video-assisted thoracic surgery in the management of Pancoast tumors. Interact Cardiovasc Thorac Surg. 2010 Dec. 11(6):721-6. [Medline].

  49. Davis GA, Knight SR. Pancoast tumors. Neurosurg Clin N Am. 2008 Oct. 19(4):545-57, v-vi. [Medline].

Table. AJCC/UICC Stages for Pancoast Tumors.
Stage T(Tumor) N (Nodes)
T3 N2
T4 Any N
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.